Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series

BACKGROUND: Relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL) is an intractable situation without sound treatment. Bruton’s tyrosine kinase (BTK) represents an attractive drug target in PCNSL. Orelabrutinib is a new-generation BTK inhibitor with high cerebrospinal fluid (CSF)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chuanwei, Cui, Yong, Ren, Xiaohui, Li, Ming, Yu, Kefu, Shen, Shaoping, Jiang, Haihui, Li, Mingxiao, Zhang, Xiaokang, Zhao, Xuzhe, Zhu, Qinghui, Lin, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243261/
https://www.ncbi.nlm.nih.gov/pubmed/35785180
http://dx.doi.org/10.3389/fonc.2022.901797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243261/
https://www.ncbi.nlm.nih.gov/pubmed/35785180
http://dx.doi.org/10.3389/fonc.2022.901797

Ejemplares similares